AMINOGLUTETHIMIDE ENZYME-INDUCTION - PHARMACOLOGICAL AND ENDOCRINOLOGIC IMPLICATIONS

被引：25

作者：

LONNING, PE

机构：

[1] Department of Therapeutic Oncology and Radiophysics, Haukeland University Hospital, Bergen

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1990年 / 26卷 / 04期

关键词：

D O I：

10.1007/BF02897223

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aminoglutethimide is an aromatase inhibitor that is successfully used for endocrine treatment of advanced breast cancer. This drug also stimulates the activity of hepatic mixed-function oxidases, increasing the metabolism of several drugs, including warfarin, digitoxin, antipyrine and theophylline. It also increases the plasma clearance rate of oestrone sulphate. As this oestrogen may be an important substrate for tumour cells, stimulation of oestrone sulphate metabolism may be a component of the mechanism of action of aminoglutethimide. © 1990 Springer-Verlag.

引用

收藏

页码：241 / 244

页数：4

相关论文

共 34 条

[1] THE EFFECT OF ACETYLATOR PHENOTYPE ON THE DISPOSITION OF AMINOGLUTETHIMIDE [J].

ADAM, AM ;

ROGERS, HJ ;

AMIEL, SA ;

RUBENS, RD .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 18 (04) :495-505

[2] INHIBITION OF PERIPHERAL AROMATIZATION OF ANDROSTENEDIONE TO ESTRONE IN POST-MENOPAUSAL WOMEN WITH BREAST-CANCER USING DELTA-1 TESTOLOLACTONE [J].

BARONE, RM ;

SHAMONKI, IM ;

SIITERI, PK ;

JUDD, HL .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1979, 49 (05) :672-676

[3] AMINOGLUTETHIMIDE (ELIPTEN-CIBA) AS AN INHIBITOR OF ADRENAL STEROIDOGENESIS - MECHANISM OF ACTION AND THERAPEUTIC TRIAL [J].

CASH, R ;

BROUGH, AJ ;

COHEN, MNP ;

SATOH, PS .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1967, 27 (09) :1239-+

[4]

CONNEY AH, 1973, CLIN PHARMACOL THER, V14, P727

[5] EFFECTIVE INHIBITION BY LOW-DOSE AMINOGLUTETHIMIDE OF PERIPHERAL AROMATIZATION IN POSTMENOPAUSAL BREAST-CANCER PATIENTS [J].

DOWSETT, M ;

SANTNER, SJ ;

SANTEN, RJ ;

JEFFCOATE, SL ;

SMITH, IE .

BRITISH JOURNAL OF CANCER, 1985, 52 (01) :31-35

[6] A COMPARISON OF THE ENDOCRINE EFFECTS OF LOW-DOSE AMINOGLUTETHIMIDE WITH AND WITHOUT HYDROCORTISONE IN POSTMENOPAUSAL BREAST-CANCER PATIENTS [J].

DOWSETT, M ;

HARRIS, AL ;

STUARTHARRIS, R ;

HILL, M ;

CANTWELL, BMJ ;

SMITH, IE ;

JEFFCOATE, SL .

BRITISH JOURNAL OF CANCER, 1985, 52 (04) :525-529

[7] ASSESSMENT OF ANTIPYRINE KINETICS BY MEASUREMENT IN SALIVA [J].

FRASER, HS ;

MUCKLOW, JC ;

MURRAY, S ;

DAVIES, DS .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1976, 3 (02) :321-325

[8] PHASE-II STUDY OF LOW-DOSE AMINOGLUTETHIMIDE 250 MG/DAY PLUS HYDROCORTISONE IN ADVANCED POSTMENOPAUSAL BREAST-CANCER [J].

HARRIS, AL ;

CANTWELL, BMJ ;

CARMICHAEL, J ;

DAWES, P ;

ROBINSON, A ;

FARNDON, J ;

WILSON, R .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (07) :1105-1111

[9] A STUDY OF ESTROGEN METABOLIC CLEARANCE RATES AND TRANSFER FACTORS [J].

HEMBREE, WC ;

BARDIN, CW ;

LIPSETT, MB .

JOURNAL OF CLINICAL INVESTIGATION, 1969, 48 (10) :1809-&

[10] 16-HYDROXYLATION OF ESTRONE-3-SULFATE AND ESTRONE IN GUINEA-PIG INVIVO [J].

HOBKIRK, R ;

NILSEN, M ;

MORI, J .

ENDOCRINOLOGY, 1978, 103 (04) :1227-1233

← 1 2 3 4 →